We are live on ! Find out more
SLXP

SALIX PHARMACEUTICALS LTD DEL
SLXP

Delisted

SLXP was delisted on the 31st of March, 2015.

308 hedge funds and large institutions have $8.26B invested in SALIX PHARMACEUTICALS LTD DEL in 2014 Q2 according to their latest regulatory filings, with 50 funds opening new positions, 109 increasing their positions, 127 reducing their positions, and 46 closing their positions.

New
Increased
Maintained
Reduced
Closed

144% more call options, than puts

Call options by funds: $199M | Put options by funds: $81.4M

21% more capital invested

Capital invested by funds: $6.82B → $8.26B (+$1.43B)

1% more funds holding

Funds holding: 304308 (+4)

9% more first-time investments, than exits

New positions opened: 50 | Existing positions closed: 46

10% less funds holding in top 10

Funds holding in top 10: 109 (-1)

14% less repeat investments, than reductions

Existing positions increased: 109 | Existing positions reduced: 127

Holders
308
Holders Change
+4
Holders Change %
+1.32%
% of All Funds
8.85%
Holding in Top 10
9
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-10%
% of All Funds
0.26%
New
50
Increased
109
Reduced
127
Closed
46
Calls
$199M
Puts
$81.4M
Net Calls
+$117M
Net Calls Change
+$65.9M
Name Holding Trade Value Shares
Change
Change in
Stake
BIM
51
BlackRock Investment Management
Delaware
$32.3M +$9.73M +88,023 +51%
MSA
52
Mason Street Advisors
Wisconsin
$31.8M +$10.5M +95,347 +59%
Renaissance Technologies
53
Renaissance Technologies
New York
$31.8M +$18.5M +167,685 +186%
CCM
54
Century Capital Management
Massachusetts
$28.7M -$14.7M -132,972 -36%
JP Morgan Chase
55
JP Morgan Chase
New York
$27.7M -$31.1M -281,113 -56%
SIMG
56
Stephens Investment Management Group
Texas
$27.3M -$1.56M -14,130 -6%
Massachusetts Financial Services
57
Massachusetts Financial Services
Massachusetts
$26.8M +$1.85M +16,754 +8%
Deutsche Bank
58
Deutsche Bank
Germany
$25.6M +$792K +7,164 +4%
BG
59
BlackRock Group
United Kingdom
$24.9M +$17.5M +157,891 +362%
N
60
Nuveen
North Carolina
$24.4M -$8.13M -73,522 -27%
Axa
61
Axa
France
$22.8M -$3.54M -31,986 -15%
NFA
62
Nationwide Fund Advisors
Ohio
$22.5M -$1.24M -11,218 -6%
California Public Employees Retirement System
63
California Public Employees Retirement System
California
$22M -$1.63M -14,720 -8%
T. Rowe Price Associates
64
T. Rowe Price Associates
Maryland
$21.8M +$1.54M +13,900 +9%
BLM
65
Bennett Lawrence Management
New York
$20.2M -$6.52M -58,960 -26%
Principal Financial Group
66
Principal Financial Group
Iowa
$19.4M -$1.49M -13,511 -8%
CCM
67
Cadian Capital Management
New York
$18.5M +$3.87M +35,000 +30%
BNP Paribas Financial Markets
68
BNP Paribas Financial Markets
France
$17.7M -$4.63M -41,932 -23%
VCM
69
Vision Capital Management
Oregon
$17.1M +$15.4M +138,993 New
MAA
70
Managed Account Advisors
New Jersey
$16.9M +$6.01M +54,416 +66%
Royal Bank of Canada
71
Royal Bank of Canada
Ontario, Canada
$16.8M +$47.1K +426 +0.3%
BBA
72
Baker Bros. Advisors
New York
$16.5M +$14.4M +130,100 +3,593%
CCP
73
Clough Capital Partners
Massachusetts
$16.5M +$4.4M +39,800 +42%
VOYA Investment Management
74
VOYA Investment Management
Georgia
$16.1M -$2.41M -21,824 -14%
EAM
75
EverPoint Asset Management
Connecticut
$16M +$14.4M +130,000 New

SLXP Hedge Fund Activity: Q2 2014 in Review

308 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in SALIX PHARMACEUTICALS LTD DEL (SLXP) for Q2 2014, worth a combined $8.26B — up 21% from $6.82B a quarter earlier.

Buyers outnumbered sellers: 50 funds opened new SLXP positions and 46 closed out — a net gain of 4 holders — while 109 added to existing stakes and 127 trimmed.

The largest buyer was Viking Global Investors, adding an estimated $148M. The largest seller was Fidelity Investments, cutting an estimated $132M.

  • 308 institutional investors held SALIX PHARMACEUTICALS LTD DEL (SLXP) as of Q2 2014, up from 304 in Q1 2014.
  • Funds reported $8.26B of SALIX PHARMACEUTICALS LTD DEL stock for Q2 2014, up 21% quarter-over-quarter.
  • 50 funds opened new SALIX PHARMACEUTICALS LTD DEL positions in Q2 2014 and 46 closed out, a net change of +4 holders.
  • The largest SALIX PHARMACEUTICALS LTD DEL buyer in Q2 2014 was Viking Global Investors, an estimated $148M added.
  • The largest SALIX PHARMACEUTICALS LTD DEL seller in Q2 2014 was Fidelity Investments, an estimated $132M sold.

Based on aggregated 13F filings for Q2 2014.